All In Biotech

Drug Trial Radar · NCT04251117

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

36

Actual

Start

Mar 1, 2020

Primary completion

Nov 29, 2024

Study completion Nov 29, 2028

Sponsor

Lead sponsor
Geneos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

Conditions

  • HCC

Interventions

  • GNOS-PV02Biological

    GNOS-PV02 delivered by intradermal injection and electroporation

  • INO-9012Biological

    INO-9012 delivered by intradermal injection and electroporation

  • PembrolizumabDrug

    Pembrolizumab administered as an intravenous (IV) infusion

  • CELLECTRA®2000 EP DeviceDevice

    CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Related Adverse EventsTime frame: From first study drug administration to approximately 57 months
  2. Neoantigen-Specific T-Cell ResponseTime frame: From baseline (pretreatment) through on-treatment assessments (approximately up to Week 12), with additional exploratory follow-up time points.
  3. Immunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow CytometryTime frame: Assessments completed at Weeks 9 or Weeks 12 post-treatment for 4 subjects.

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Auckland Clinical Studies

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.